WHO advises doctors to not use Remdesivir to treat COVID-19


The WHO advises not to use Gilead Science Inc’s Remdesivir to treat hospitalised COVID-19 patients less than a month after U.S. granted it approval. The medicine has been used in more than 50 countries to reduce recovery time of COVID-19 patients. There is currently no evidence that introduced deaths, instead “it has no meaningful effect”. The limited study was weighted along “Relatively high cost and resource implications” associated with Remdesivir.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More